THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF THE MARKET ABUSE REGULATION (596/2014/EU) AS IT FORMS PART OF UK DOMESTIC LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("MAR").                                                                                   

                                                                                                        Renalytix plc

("Renalytix" or the "Company")

Growing collaboration with New York Kidney & Hypertension Medicine

Renalytix collaborates with NYKHM to bring kidneyintelX.dkd testing to underserved communities

in the Greater New York area, enabling access for over 2,000 patients

LONDON and NEW YORK, 3 June 2025 - Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision medicine company, announces a collaboration with New York Kidney & Hypertension Medicine (NYKHM) to expand access to kidneyintelX.dkd, the only FDA-approved and Medicare reimbursed prognostic test to support early-stage risk assessment in patients with type 2 diabetes and chronic kidney disease stages 1-3b.

NYKHM is a national leader in applying EHR-integrated analytics and comprehensive, personalized treatment plans to manage chronic kidney disease in  communities across Queens, Brooklyn, and the greater New York metropolitan area. The Renalytix-NYKHM collaboration will expand the use of kidneyintelX.dkd blood testing in underserved, high-risk communities to mitigate progressive decline in kidney function and help preserve patient health and quality of life. The program is expected to enable access to over 2,000 patients for kidneyintelX.dkd prognostic blood testing, complementing Renalytix expanded access programs throughout the Northeast region.

Enhanced insight into kidney function can help NYKHM physicians and their patients develop personalized treatment plans to reduce the risk of kidney, cardiovascular, and metabolic disease, further enabling long-term wellness. The kidneyintelX.dkd test is FDA-approved, reimbursed by Medicare, and recommended in international kidney disease clinical guidelines.

As part of the collaboration, Renalytix and NYKHM will also engage in:

·    Community-Based Provider Education: Coordinating joint educational sessions for primary care physicians to promote early-stage CKD detection and risk stratification.

·      Patient Awareness Initiatives: Launching a public-facing campaign to educate patients about kidney disease risk factors and the importance of proactive management.

Dr. Premila Bhat, Partner, NYKHM and Managing Partner, Tidal Dialysis, LLC, said: "We are dedicated to bringing the latest medical innovations to our communities to ensure that our patients with chronic kidney disease can take charge of their health and wellness. The kidneyintelX.dkd test enables both physicians and patients to understand kidney disease risk early, so we can take timely action and deliver the most effective care available today."

James McCullough, CEO of Renalytix, commented: "Dr. Bhat and her team represent exactly the type of forward-thinking, patient-centered partners with whom we want to align. This partnership is a clear demonstration of how early prognosis, combined with community-based care, can shift the paradigm toward earlier detection and better outcomes in kidney disease."

The person responsible for arranging for the release of this announcement on behalf of Renalytix is James McCullough, CEO.

For further information, please contact:

About Renalytix (www.renalytix.com)

Renalytix (LSE: RENX) (OTCQB: RNLXY) is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes. Renalytix has received FDA approval and Medicare reimbursement for kidneyintelX.dkd which is now offered commercially in the United States.

Unrecognized and uncontrolled kidney disease remains one of the largest barriers to controlling cost and suffering in the United States and the United Kingdom's medical system, affecting over 14 million and 8 million people, respectively. After five years of development and clinical validation, kidneyintelX.dkd is the only FDA-approved and Medicare reimbursed prognostic tool capable of understanding a patient's risk with kidney disease early where treatment has maximal effect. kidneyintelX.dkd is now being deployed across large physician group practices and health systems in select regions of the United States.

The over 15,000 patients that have been tested by kidneyintelX.dkd have produced a substantial body of real-world performance data. In patient populations where kidneyintelX.dkd has been deployed, a demonstrated and significant increase in diagnosis, prognosis, and treatment rates have been recorded. kidneyintelX.dkd now has full reimbursement established by Medicare, the largest insurance payer in the United States, at $950 per reportable result. kidneyintelX.dkd is also recommended for use in the international chronic kidney disease clinical guidelines (KDIGO).

KidneyIntelX is based on technology developed by Mount Sinai faculty and licensed to Renalytix AI, Inc. Mount Sinai faculty members are co-founders and equity owners in the Company. In addition, the Icahn School of Medicine at Mount Sinai has equity ownership in Renalytix.

About New York Kidney & Hypertension Medicine (www.nykhm.com )

New York Kidney & Hypertension Medicine (NYKHM) was established in 1988 to serve the populations of Brooklyn and Queens in New York City. Their goal is to transform diagnosis, risk stratification and CKD care delivery for patients in a seamless fashion.